Full Press Release Details
electroCore Announces Shareholder Letter and Full-Year
2021 Business Update
Company anticipates full-year 2021 revenue of approximately
$5.5 million, an approximately 55% increase over full-year 2020
ROCKAWAY, NJ, Jan. 18, 2022 -- electroCore, Inc. (Nasdaq:
ECOR) today published a letter from the company's Board of Directors to shareholders. The letter is included in its entirety,
We continue to be excited about the long-term prospects of
our Company and would like to share some of the reasons for our optimism.
We are investing in marketing initiatives that we believe will
make our gammaCore therapy available directly to consumers through multiple channels at a very compelling price. Among these channels
are our newly launched e-commerce storefronts in the United Kingdom (UK) and the United States (US). Headache patients can now access
gammaCore therapy simply by going to our web site and filling out a short questionnaire. The questionnaire is reviewed by a Health Care
Professional who can write prescriptions for the therapy and moved into a shopping cart on our e-commerce storefront. After the gammaCore
product is received by the patient, our customer experience team provides a variety of hands-on tools for patient training and support.
Our team then stays in regular contact with the patient, providing further support during the course of the therapy and reminders about
refill opportunities.
In parallel with our online stores, we have launched our gConcierge
and gCDirect programs for a growing number of physician prescribers in the US. These new programs allow physicians to offer their patients
the opportunity to purchase gammaCore therapy directly through their offices (gConcierge) or directly from us (gCDirect). We have broadened
our call points from the traditional neurology headache specialists to include a wider range of medical providers who manage patients'
headache conditions, including those in primary care, women's health, pain management, functional and integrative medicine, as well
as chiropractors and Doctor of Pharmacy (PharmDs). In total, we have had approximately 200 prescribers write scripts through the gConcierge
and gCDirect programs, all of whom have patients that can be supported by our in-house customer experience team.
With the early growth and promise of success among these newly
established, streamlined consumer access initiatives, we are planning to aggressively ramp up our spending on Direct-to-Consumer advertising
and other promotional activities. Our goal is to drive consumer awareness and funnel that interest to our e-commerce stores and provider
In our legacy business channels, we have continued to grow
our Department of Veterans Affairs (VA) and Department of Defense (DoD) business in the United States, our National Health Service (NHS)
business in the United Kingdom, and our distributor relationships around the world. We plan to continue to invest in growth from these
channels as we move through 2022, strengthened by our Direct-to-Consumer initiatives and advertising spend. While we continue to work
towards expanding commercial insurance coverage for gammaCore in the United States, we recognize the barrier high deductible plans represent
for many Americans and anticipate they will benefit significantly from our newly launched cash pay programs, even when coverage is available.
Looking beyond primary headache, we anticipate reporting on
our multiple clinical programs over the course of 2022. Ongoing trials continue to be conducted with our gammaCore therapy in secondary
headache, traumatic brain injury (concussion), post traumatic stress disorder (PTSD), stroke, opioid use disorder, Parkinson's,
postoperative ileus, and other potential indications. We anticipate many of these programs will generate results that can support expanded
labels and additional uses for gammaCore nVNS therapy, and support potentially expanded total addressable markets for our therapy. We
believe nVNS therapy will be highly differentiated in conditions like concussion, PTSD, stroke, and opioid use disorder where there are
few effective therapies currently.
Finally, as we expand our commercial initiatives, we are also
looking beyond organic growth opportunities and exploring ways to accelerate our growth through acquisitions that enhance and leverage
the distribution channels we are developing.
We have also continued to expand our intellectual property
portfolio, especially in digital health and smartphone-integrated and smartphone-connected non-invasive therapy, which may provide us
with opportunities to leverage our patents. We believe our intellectual property will be the foundation of next generation neuromodulation
devices in the market, including our own nVNS devices.
We look forward to enabling health care providers in their
use of Remote Patient Monitoring and Remote Therapeutic Monitoring, which have been identified as critical areas for practice revenue
growth in the future.
Preliminary Unaudited Financial Results for Full-Year 2021
Full-Year 2021 Revenue: electroCore anticipates full-year
2021 revenue will be approximately $5.5 million. This would represent an approximately 55% increase over full-year 2020 revenue of $3.5
Government Channels: During the full-year 2021, the
Company expects to recognize revenue of approximately $3.3 million pursuant to the VA and DoD originating prescriptions or in excess of
60% growth as compared to $2.0 million during the full-year 2020. One hundred VA and DoD military treatment facilities have purchased
gammaCore products through December 31, 2021, as compared to 71 facilities through full-year 2020. With roughly 1,800 Federal Supply Schedule
(FSS) eligible treatment facilities to which we have access, we believe the US government channel remains a significant opportunity for
Outside of the U.S.: During the year-ending December
31, 2021, electroCore expects to recognize revenue of approximately $1.5 million outside of the US, as compared to $1.1 million during
the fiscal 2020, representing year-over-year growth of approximately 36%. These results are primarily due to the stellar work and dedication
of our UK subsidiary, led by Iain Strickland VP, Global Sales and Strategy, who gracefully navigated the funding transition for our gammaCore
product in England from the NHS Innovation and Technology Payment (ITP) Program to the MedTech Funding Mandate Policy 2021/2022.
Commercial: During the year-ending December 31, 2021,
electroCore expects to recognize revenue of approximately $680,000 or approximately 89% growth compared to $360,000 in full-year 2020.
These figures include revenues from the commercial payer and cash pay channels in the US through our new online store, our gConcierge,
and our gCDirect programs discussed above.
Research and Development: During fiscal 2021, the Company
continued to make progress across its clinical programs. The Company received four new 510(k) clearances. Additionally, on January 11,
2022, the Company received Breakthrough Designation from the Food and Drug Administration for the treatment of PTSD.
Cash: The Company ended the fourth quarter of 2021 with
approximately $34.7 million of cash, cash equivalents and marketable securities. Net cash used in operations is expected to be approximately
$13.6 million for the full-year 2021 as compared to $20.1 million and $45.1 million reported in 2020 and 2019, respectively.
During 2021, we accessed the capital markets to strengthen
our balance sheet by approximately $25.7 million, which will give us the resources to make the transformational changes to our business
we envision for the future. As we move into 2022, we continue to position the Company to take advantage of additional steps that could
expand our business including, for example through acquisitions, by enabling the Company to access the capital markets as opportunities
We are proud of the progress we have made and are excited
about the future. Thank you for your continued support.
electroCore Board of Directors
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine
company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on
the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache
and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents,
and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
gammaCoreTM (nVNS) is the first non-invasive, hand-held
medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild
electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can
be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed
on a patient's neck over the vagus nerve, gammaCore stimulates the nerve's afferent fibers, which may lead to a reduction
of pain in patients.
gammaCore (nVNS) is FDA cleared in the United States for adjunctive
use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache
in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore
is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal
Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
Safety and efficacy of gammaCore have not been evaluated in
the following patients: